

Supplementary material

Immunogenicity and efficacy of homologous and heterologous NDV and MVA SARS-CoV-2 vaccines in mice and hamsters

Patricia Pérez^{1,2,#}, Kaijun Jiang^{3,4,5,#}, Irene González-Domínguez³, Daniel Rodríguez-Martín¹, Adam Abdeljawad³, Anastasija Cupic^{3,4}, Stefan Slamanig^{3,6}, Sara Flores¹, María A. Noriega¹, Pedro J. Sánchez-Cordón⁷, Nicholas Lemus³, Tsoi Ying Lai³, Weina Sun³, Mariano Esteban¹, Adolfo García-Sastre^{3,5,8,9,10,11*} & Juan García-Arriaza^{1,2,*}

¹ Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), 28049 Madrid, Spain.

² Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.

³ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

⁴ Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

⁵ Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

⁶ Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands

⁷ Pathology Department, Centro de Investigación en Sanidad Animal (CISA), Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Consejo Superior de Investigaciones Científicas (CSIC), Valdeolmos, Madrid, Spain.

⁸ Department of Medicine, Division of Infectious Disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

⁹ The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.


¹⁰ The Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

¹¹ Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Contributed equally.

* Address correspondence to Adolfo García-Sastre (Adolfo.Garcia-Sastre@mssm.edu) and Juan García-Arriaza (jfgarcia@cnb.csic.es)

Supplementary Figure 1



Supplementary Figure 1. Lung pathology in immunized hamsters at day 5 post-challenge. Left lung lobes of hamsters from the different homologous or heterologous vaccination groups, recipient groups (RGs) and healthy control group were collected at day 5 post-challenge, fixed in 4% paraformaldehyde, cut into 5 μ m sections and stained with hematoxylin and eosin (H&E). Representative images are indicated. The scale bar (bottom left or bottom right) represents 100 μ m in the H&E images.

Supplementary Table 1. Scoring system used to define the pathological changes in the lungs of hamsters.

Score	Area affected	Epithelial degeneration/necrosis	Inflammation
0	none	none	none
1	5-10%	Minimal; scattered cell necrosis/ vacuolation affecting 5 to 10% of tissue section	Minimal; scattered inflammatory cells affecting 5-10% of tissue section
2	10-25%	Mild; scattered cell necrosis/ vacuolation	multifocal, few inflammatory cells
3	25-50%	Moderate; multifocal vacuolation or sloughed/necrotic cells	Thin layer of cells (<5 cell layer thick)
4	50-75%	Marked; multifocal/segmental necrosis, epithelial loss/effacement	Thick layer of cells (>5 cell layer thick)
5	>75%	Severe; coalescing areas of necrosis, parenchymal effacement	Confluent areas of inflammation